This site uses cookies to provide you with a more responsive and personalized service. By using this site you agree to our use of cookies. Please read our cookie notice for more information on the cookies we use and how to delete or block them.

Global > United States > Industries > Health Care Providers > Health Reform > Life Sciences Health Reform

Global site selector

Life Sciences Health Reform

What is your business DNA?

No matter how transformational a discovery or breakthrough is, it doesn’t automatically translate into a market success. Leading organizations live at the intersection of new science and spot-on business acumen. Life is changing at a remarkable rate in the pharmaceutical, biotechnology and medical products businesses. Deloitte’s Life Sciences health reform practice can help companies address these changes and achieve their business goals. What’s the DNA of your business?

More Featured insights

Value-based pharmaceutical pricing: Deloitte Insights video
To transition from volume-based models to value-based pricing, companies must start with the basics. Watch this episode of Deloitte Insights to learn more.
Value-based pricing for pharmaceuticals: Implications of the shift from volume to value
In a new value-driven health care system, payment linked to performance is a paradigm shift that calls for pharmaceutical companies to innovate in product commercialization and pricing. This Issue Brief summarizes what is known to date about value-based pricing and identifies opportunities for additional exploration.
Life sciences and health reform: No going back
Tune into the latest episode of Deloitte Insights to learn more about the impact of health care reform on the life sciences industry.